Engrail is a technology company that specializes in providing advanced data analytics and machine learning solutions. The company focuses on helping businesses optimize their operations, enhance decision-making, and improve overall performance through the use of cutting-edge AI-driven platforms.

We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Nan Fung Life Sciences

Engrail Therapeutics

At Engrail, our purpose is to deliver transformational therapies that improve the lives of patients with devastating neuropsychiatric and neurodevelopmental disorders. Developing new treatments for tough disorders is challenging and expensive. However, we are committed to advancing the development of our pipeline to realize our purpose. 

Today, we are thrilled to announce the close of our oversubscribed $157M Series B Financing Round. Thank you to an A+ syndicate of investors for believing in our team and pipeline of transformational therapies. This includes: F-Prime Capital, Norwest Venture Partners, Forbion, Red Tree Venture Capital, RiverVest Venture Partners, Ysios Capital, Longwood Fund, Eight Roads, Pivotal Life Sciences, and others.

Please see: https://lnkd.in/gw35_KTe


On the rarest of days (February 29), we recognize the courage of all patients with rare diseases, their caregivers, and clinicians. 

Although a rare disease is defined as one with <200,000 patients in the US, collectively over 30 million, or 1 in 10 Americans, are directly impacted. Patients deserve solutions, and we are proud to work towards their development at Engrail.

As we enter the home stretch of 2023, we reflect back on the triumphs, challenges, and new opportunities afforded to us. We are thankful for our great team, investors, trusted advisors, and Industry partners. 

On behalf of Engrail, we wish you and your loved ones a very happy and memorable holiday season!

Please allow us to welcome Dr. Quentin McCubbin as Chief Technical Officer at Engrail!

Quentin will be responsible for leading all aspects of technical operations and drug manufacturing for Engrail. This is particularly exciting as we lay the groundwork for the future ENX-102 phase 3 program as well as first-in-human studies for ENX-104, ENX-105, and the clinical program for ENX-103. 

Quentin brings over 25 years of chemistry, formulation, manufacturing, and leadership experience to Engrail. Recently, Quentin was Chief Manufacturing Officer at Frequency Therapeutics and Head of Technical Operations at Cerevel Therapeutics. Prior to those roles Quentin spent over 15 years in progressive roles at Takeda Pharmaceuticals and its subsidiaries.  

Welcome to the family Quentin!

#neuroscience #pipeline #leadership #cmc #manufacturing #drugdevelopment

COM:ENGRAIL

Engrail

Analysis Not Available